Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

India's new envoy to Canada rejected Foreign Minister Anita Anand's claim that New Delhi has agreed to restore Canada's full ...

ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that it will present initial Phase 1 clinical data for ADX ...

Omeros Corporation maintained with Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for ...

Omeros' stock surged over 150% after licensing zaltenibart to Novo Nordisk for $240M upfront, plus milestones and royalties.

Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 10 - 12, 2025 in Boston, MA Fireside chat on November 11 at 2:30 PM ET InflaRx will also conduct one-on-one investor meetings ...

The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called ...

Similar to the numeric system in place in Europe and Australia, Equibase Ratings could be used as early as Oct. 24 at Santa ...

Role Combat Vessels will be able to project naval power further, and for longer, than previous Singaporean warships.

New research suggests that trying to change people's climate habits won't hurt support for big picture solutions.

Equibase Company, the Thoroughbred industry’s official database for racing information, has launched a new performance-based ...